Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 6Solid Tumors 4Neoplasms 4Lymphoma 3Lymphoma, Non-Hodgkin 2Leukemia, B-Cell 2Solid Tumor 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Recurrence 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Mycosis Fungoides 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoid Malignancy 1Leukemia, Myeloid, Acute 1Leukemia 1Hepatitis C 1Hepatitis B 1Hematologic Neoplasms 1Fibrosis 1Carcinoma, Hepatocellular 1Advanced Lung Non-Squamous Non-Small Cell Carcinoma 1

Interventions

navitoclax 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lymphoid Malignancy × navitoclax × Clear all
NCT00982566 2017-11-21

Assess the Oral Bioavailability of a New ABT-263 Formulation in Subjects With Cancer

AbbVie

Phase 1 Completed
37 enrolled
Other solid neoplasm

Lymphoid Malignancy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡